Regencell Bioscience Files Interim Financials for Dec 31, 2024
Ticker: RGC · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1829667
| Field | Detail |
|---|---|
| Company | Regencell Bioscience Holdings LTD (RGC) |
| Form Type | 6-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, interim-results, sec-filing
TL;DR
Regencell 6-K filed: interim financials for 6 months ending Dec 31, 2024. Check financials.
AI Summary
Regencell Bioscience Holdings Limited has filed a Form 6-K on June 30, 2025, to furnish its unaudited condensed consolidated interim balance sheets and statement of operations and comprehensive loss for the six months ended December 31, 2024. This filing is made pursuant to Nasdaq Rule 5250(c)(2).
Why It Matters
This filing provides investors with an update on Regencell's financial performance and position as of the end of 2024, allowing for assessment of the company's operational health.
Risk Assessment
Risk Level: low — This filing is a routine submission of financial information and does not contain new material events or significant financial changes.
Key Players & Entities
- Regencell Bioscience Holdings Limited (company) — Filer of the report
- Nasdaq Rule 5250(c)(2) (rule) — Rule under which the financial information is furnished
- December 31, 2024 (date) — End date of the reporting period for the financial statements
- June 30, 2025 (date) — Filing date of the Form 6-K
FAQ
What specific financial statements are being furnished in this Form 6-K?
The unaudited condensed consolidated interim balance sheets and statement of operations and comprehensive loss for the six months ended December 31, 2024, are being furnished.
Under which rule is Regencell Bioscience Holdings Limited furnishing this information?
The information is being furnished pursuant to Nasdaq Rule 5250(c)(2).
What is the reporting period covered by the furnished financial statements?
The reporting period is the six months ended December 31, 2024.
Is this filing an annual report or an interim report?
This filing is a Form 6-K, which is a report of foreign private issuers and is used to furnish interim financial information.
What is the filing date of this Form 6-K?
The Form 6-K was filed on June 30, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding Regencell Bioscience Holdings Ltd (RGC).